1-4 of 4
Serge A. Jabbour
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis

Free
Jean-Etienne Poirrier, Juliana L. Meyers, Saurabh P. Nagar, Brandon J. Patterson, Lisa I. Glasser, Serge A. Jabbour
Journal: Diabetes Care
Diabetes Care 2022;45(11):2585–2593
https://doi.org/10.2337/dc21-2053
Published: 23 September 2022
View articletitled, Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis
Open the PDF for Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis in another window
Journal Articles

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

Free
Serge A. Jabbour, Juan P. Frías, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C. David Sjöström, Cristian Guja
Journal: Diabetes Care
Diabetes Care 2020;43(10):2528–2536
https://doi.org/10.2337/dc19-1350
Published: 18 August 2020
View articletitled, Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Open the PDF for Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial in another window
Journal Articles

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Free
Serge A. Jabbour, Juan P. Frías, Elise Hardy, Azazuddin Ahmed, Hui Wang, Peter Öhman, Cristian Guja
Journal: Diabetes Care
Diabetes Care 2018;41(10):2136–2146
https://doi.org/10.2337/dc18-0680
Published: 06 August 2018
View articletitled, Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Open the PDF for Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Open Access
Serge A. Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh,, for the Study 10 Group
Journal: Diabetes Care
Diabetes Care 2014;37(3):740–750
https://doi.org/10.2337/dc13-0467
Published: 11 February 2014
View articletitled, Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Open the PDF for Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in another window
Includes: Multimedia, Supplementary data